Invesco’s NewAmsterdam Pharma NAMS Stock Holding History

Invesco’s Portfolio NAMS Stock Details NAMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$224K	Sell	6,617 -674	-9%	-$22.2K	﹤0.01%	3546
2026 Q1	$233K	Buy	7,291 +1,330	+22%	+$43.3K	﹤0.01%	3433
2025 Q4	$209K	Sell	5,961 -98,715	-94%	-$3.59M	﹤0.01%	3509
2025 Q3	$2.98M	Sell	104,676 -29,359	-22%	-$704K	﹤0.01%	2461
2025 Q2	$2.43M	Buy	134,035 +15,101	+13%	+$275K	﹤0.01%	2503
2025 Q1	$2.43M	Sell	118,934 -31,625	-21%	-$703K	﹤0.01%	2467
2024 Q4	$3.87M	Buy	+150,559	New	+$3.2M	﹤0.01%	2372

Other funds holding NAMS

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

DFO

Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

Invesco's NAMS Position: Q2 2026 in Review

Invesco reduced its NewAmsterdam Pharma (NAMS) stake by 9.2% in Q2 2026, selling an estimated $22.2K and leaving 6,617 shares worth $224K. The position accounts for ﹤0.01% of the portfolio, ranked #3546.

Invesco first reported a position in NAMS in Q4 2024 and has held it in 7 quarters since. The position peaked at $3.87M in Q4 2024. 194 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

Invesco held 6,617 shares of NewAmsterdam Pharma worth $224K as of Q2 2026.
Invesco sold 674 NewAmsterdam Pharma shares in Q2 2026, an estimated $22.2K.
NewAmsterdam Pharma made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #3546 holding.
Invesco first reported a position in NewAmsterdam Pharma in Q4 2024 and has held it in 7 quarters since.
Invesco's NewAmsterdam Pharma position peaked at $3.87M in Q4 2024.
194 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.